Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. H.C. Wainwright & Co. is acting as co-manager for the offering.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target raised to $29 from $26 at BofA
- Denali Therapeutics price target raised to $31 from $30 at Wedbush
- Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
- Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs
- Denali Therapeutics Secures $275M Royalty Funding Deal